Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Payables (2016 - 2025)

Historic Payables for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $190.8 million.

  • Amphastar Pharmaceuticals' Payables rose 2451.65% to $190.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $190.8 million, marking a year-over-year increase of 2451.65%. This contributed to the annual value of $157.1 million for FY2024, which is 6821.65% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Payables stood at $190.8 million for Q3 2025, which was up 2451.65% from $166.6 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Payables high stood at $222.7 million for Q3 2023, and its period low was $84.2 million during Q4 2022.
  • Moreover, its 5-year median value for Payables was $109.6 million (2021), whereas its average is $130.7 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Payables soared by 13249.3% in 2023, and later crashed by 3968.26% in 2024.
  • Amphastar Pharmaceuticals' Payables (Quarter) stood at $89.5 million in 2021, then fell by 5.92% to $84.2 million in 2022, then rose by 10.83% to $93.4 million in 2023, then soared by 68.22% to $157.1 million in 2024, then increased by 21.51% to $190.8 million in 2025.
  • Its last three reported values are $190.8 million in Q3 2025, $166.6 million for Q2 2025, and $175.9 million during Q1 2025.